Meng Wang

Meng Wang

Auto-generated profile, based on publicly available information

Meng Wang

State Key Laboratory of Palaeobiology and Stratigraphy, Nanjing Institute of Geology and Palaeontology, Chinese Academy of Sciences, Nanjing, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Earth and Planetary Science Letters
Verified
Journal Article
Closed access
MWMeng Wang
Meng Wang
HCHonghan Chen
Honghan Chen
CHChunju Huang
Chunju Huang
DKDavid B. Kemp
David B. Kemp
TXTianwu Xu
Tianwu Xu
MLMingsong Li
Mingsong Li

9 July 2024 in Earth and Planetary Science Letters
Verified
Journal Article
Closed access
MWMeng Wang
Meng Wang
MLMingsong Li
Mingsong Li
EHElizabeth A. Hajek
Elizabeth A. Hajek
DKDavid B. Kemp
David B. Kemp
YWYujing Wu
Yujing Wu
ZJZhijun Jin
Zhijun Jin

6 July 2021 in Oncology Reports
Verified
Journal Article
Open access
PDF file
YLYang Liu
Yang Liu
NLNa Li
Na Li
MWMeng Wang
Meng Wang
YZYan-Hua Zhang
Yan-Hua Zhang
LYLu-Da Yan
Lu-Da Yan
SLShunshe Luo
Shunshe Luo
Non‑small cell lung cancer (NSCLC), which accounts for ~85% of all lung cancer cases, is commonly diagnosed at an advanced stage and has a high patient mortality rate. Despite the increasing availability of treatment strategies, the prognosis of patients with NSCLC remains poor, with a low 5‑year survival rate. This poor prognosis may be associated with the tumor heterogeneity of NSCLC, as well as its acquisition and intrinsic resistance to therapeutic drugs. It has been suggested that combination therapy with telomerase inhibition may be an effective strategy for the treatment of drug‑sensitive and drug‑resistant types of cancer. Telomerase is the key enzyme for cell survival, and ~90% of human cancers maintain telomeres by activating telomerase, which is driven by the upregulation of telomerase reverse transcriptase (TERT). Several mechanisms of telomerase reactivation have been described in a variety of cancer types, including TERT promoter mutation, epigenetic modifications via a TERT promoter, TERT amplification, and TERT rearrangement. The aim of the present study was to comprehensively review telomerase activity and its association with the clinical characteristics and prognosis of NSCLC, as well as analyze the potential mechanism via which TERT activates telomerase and determine its potential clinical application in NSCLC. More importantly, current treatment strategies targeting TERT in NSCLC have been summarized with the aim to promote discovery of novel strategies for the future treatment of NSCLC.

1 November 2019 in Journal of Asian Earth Sciences
Verified
Journal Article
Closed access
MWMeng Wang
Meng Wang
QLQing Li
Qing Li
FCFeng Cai
Feng Cai
JLJie Liang
Jie Liang
GYGuijing Yan
Guijing Yan
YCYimin Cao
Yimin Cao

2 November 2015 in Science China Earth Sciences
Verified
Journal Article
Closed access
PDF file
MWMeng Wang
Meng Wang
FCFeng Cai
Feng Cai
QLQing Li
Qing Li
JLJie Liang
Jie Liang
GYGuiJing Yan
GuiJing Yan
GHGaoWei Hu
GaoWei Hu

3 March 2023 in Earth and Planetary Science Letters
Verified
Journal Article
Closed access
MWMeng Wang
Meng Wang
MLMingsong Li
Mingsong Li
DKDavid B. Kemp
David B. Kemp
JLJan Landwehrs
Jan Landwehrs
ZJZhijun Jin
Zhijun Jin